Pay in installments of $7.89 with
,
and
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 1 - Aug 6
For Your Every Summer RSVP, with Code: SUMMER15
Description
Colnatur Condroactiv 30 Sobres 8,8 G Sabor PiñaColnatur Condroactiv 30 Sobres 8,8 G Sabor Pia Descubre el Colnatur Condroactiv 30 Sobres 8,8 G con delicioso sabor a pia, un suplemento ideal para el cuidado de tus articulaciones. INDICACIONES Este producto est diseado para personas que buscan mantener la salud y movilidad de sus articulaciones, especialmente aquellas que practican deporte o que sufren de desgaste articular. MODO DE EMPLEO Se recomienda tomar un sobre al da, disuelto en agua, leche

Shipping Notes
- Free Standard Shipping on $100+ Orders to the USA.
- Except Preorder products are shipped in 48 hours.
- Delivery to the USA:
- Standard Shipping : 3-10 business days
- If time is of the essence, please consider selecting expedited delivery for faster service.
Exchange/Return Notes
- We offer a 30-day return/exchange service after receiving.
- Final sale items are not eligible for returns or exchanges.
- To process your return/exchange, please contact us at [email protected]
- Please click here for more details>>> Return & Exchange Policy
4.6 ★★★★★
Based on 853 reviews
Sort
Product Reviews
★★★★★ 4
Good for pain relief
My mother found it very effective in decreasing inflammation in her joints due to high uric acid levels.
WAS THIS REVIEW HELPFUL?YesReportShare
Reviewed in the United States on April 23, 2019
★★★★★ 5
Very good
I like
WAS THIS REVIEW HELPFUL?YesReportShare
Reviewed in the United States on November 6, 2025
★★★★★ 5
Don’t forget to take it.
It is working best that I can tell, will let you later
WAS THIS REVIEW HELPFUL?YesReportShare
Reviewed in the United States on August 5, 2025
★★★★★ 3
No me sirvio
No cumplió para lo que fue comprado
WAS THIS REVIEW HELPFUL?YesReportShare
Reviewed in the United States on November 9, 2023
★★★★★ 5
Good product
Good product
WAS THIS REVIEW HELPFUL?YesReportShare
Reviewed in the United States on March 25, 2025




